Therapeutic Response

CD20 + status confers therapeutic sensitivity to Cyclophosphamide in combination with Prednisolone, Rituximab, and Vincristine in patients with Follicular Lymphoma.

Statements

Source and description
Rituxan (rituximab) [product monograph]. HC. Health Canada approved rituximab for the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP chemotherapy.